Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well brentuximab vedotin works in treating patients with CD30
positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies,
such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and
spread.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) Seattle Genetics, Inc.